Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Amplification”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07087223
What this trial is testing

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute 42
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782
What this trial is testing

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 278
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Early research (Phase 1)Active Not RecruitingNCT02609776
What this trial is testing

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC 751
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06885840
What this trial is testing

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 100
Not applicableUnknownNCT06022276
What this trial is testing

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Who this might be right for
Solid TumorEGFR Amplification
Tianjin Medical University Second Hospital 46
Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06452433
What this trial is testing

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 91
Testing effectiveness (Phase 2)UnknownNCT05163249
What this trial is testing

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Guangdong Association of Clinical Trials 44
Testing effectiveness (Phase 2)Study completedNCT03888092
What this trial is testing

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Sunshine Lake Pharma Co., Ltd. 81
Large-scale testing (Phase 3)Looking for participantsNCT06829459
What this trial is testing

Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 350
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Testing effectiveness (Phase 2)Study completedNCT03356223
What this trial is testing

Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6

Who this might be right for
Head and Neck CancerAdvanced CancerMetastatic Cancer
Centre Leon Berard 25
Large-scale testing (Phase 3)Study completedNCT00320385
What this trial is testing

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 296
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Not applicableStudy completedNCT05290441
What this trial is testing

Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia

Who this might be right for
Pneumonia, ViralCOVID-19 PneumoniaEGFR Amplification
Bursa Yuksek Ihtisas Training and Research Hospital 65
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Next Page